[Cardiac Amyloidosis: Experience in a National Reference Cardiovascular Institute]. / Amiloidosis Cardíaca: Experiencia en un Instituto Cardiovascular de Referencia Nacional.
Arch Peru Cardiol Cir Cardiovasc
; 1(2): 75-84, 2020.
Article
en Es
| MEDLINE
| ID: mdl-38572335
ABSTRACT
Objectives:
To determine the clinical, imaging and laboratory characteristics and one year after diagnosis survival of patients with cardiac amyloidosis in a national reference hospital. Materials andmethods:
Case series study. We evaluated the clinical characteristics, complementary examinations and survival of patients with cardiac amyloidosis diagnosed, treated and followed up in the Clinical Cardiology service of the National Cardiovascular Institute - INCOR EsSalud in Lima, Peru.Results:
We found eight patients with diagnosis of cardiac amyloidosis. The median age was 64.5 years and 75% were male. The etiology of cases was unspecified cardiac amyloidosis (25%), transthyretin cardiac amyloidosis (37.5%), and light chain cardiac amyloidosis (37.5%). Symptomatic heart failure (NYHA II-III) was the most common initial presentation symptom (87.5%). The most frequent extracardiac manifestations were sensory-motor neuropathy (62.5%), musculoskeletal (37.5%), nephropathy (25%), bilateral carpal tunnel syndrome (25%), monoclonal gammopathies (25%) and refractory pleural effusion (25 %). Survival at one year was 75% and the cause of the 2 deaths was sudden death.Conclusions:
In this study of cardiac amyloidosis at a specialized center, the most frequent clinical manifestations were heart failure and sensory-motor neuropathy. Mortality was 25% per year, and in all cases as sudden death.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
Es
Revista:
Arch Peru Cardiol Cir Cardiovasc
Año:
2020
Tipo del documento:
Article
Pais de publicación:
Perú